A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 10, 2005, Pages 5523-5527

  Araya, Kaori ^a   Fukumoto, Seiji ^a   Backenroth, Rebecca ^b   Takeuchi, Yasuhiro ^a   Nakayama, Kounosuke ^a   Ito, Nobuaki ^a   Yoshii, Nozomi ^c   Yamazaki, Yuji ^c   Yamashita, Takeyoshi ^c   Silver, Justin ^b   Igarashi, Takashi ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Pharmaceutical Research Laboratory   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHENYLALANINE; PHOSPHATE; SERINE;

ADULT; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CASE REPORT; CODON; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FUNCTION; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; MALE; MAMMAL CELL; MOLECULAR WEIGHT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR CALCINOSIS; WESTERN BLOTTING; WILD TYPE;

ADULT; BLOTTING, WESTERN; CALCINOSIS; CELLS, CULTURED; CULTURE MEDIA, CONDITIONED; DNA, ANTISENSE; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MOLECULAR WEIGHT; MUTATION; NEOPLASMS; PEDIGREE; PHOSPHATES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VITAMIN D;

MAMMALIA;

EID: 26244454531     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-0301     Document Type: Article

References (19)

1. Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3 encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581
2. Lyles KW, Halsey DL, Friedman NE, Lobaugh B 1988 Correlations of serum concentrations of 1,25-dihydroxyvitmain D, phosphorus, and parathyroid hormone in tumoral calcinosis. J Clin Endocrinol Metab 67:88-92
3. Fukumoto S, Yamashita T 2002 Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin. Curr Opin Nephrol Hypertens 11:385-389
4. The ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
5. Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
6. Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
7. Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Juppner H 2003 Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656-1663
8. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 19:429-435
9. Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of FGF23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113:561-568
10. Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Juppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432
11. Benet-Pages A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390
12. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 (FGF23) causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427
13. Benet-Pages A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom TM 2004 FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462
14. Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology 143:3179-3182
15. Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979-3982
16. 3 and phosphorus in vivo. J Biol Chem 280:2543-2549
17. Ferrari SL, Bonjour JP, Rizzoli R 2004 Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 90:1519-1524
18. Frishberg Y, Araya K, Rinat C, Yamazaki Y, Feinsterin S, Becker-Cohen R, Yamashita T, Fukumoto S 2003 Cortical hyperostosis-hyperphosphatemia syndrome associated with augmented processing and decreased biologically active FGF-23. J Am Soc Nephrol 14:208A (Abstract)
19. Harmer NJ, Pellegrini L, Chirgadze D, Fernandez-Recio J, Blundell TL 2004 The crystal structure of fibroblast growth factor (FGF) 19 reveals novel features of the FGF family and offers a structural basis for its unusual receptor affinity. Biochemistry 43:629-640